Lori M. Neal

Lori M. Neal

Auto-generated profile, based on publicly available information

Lori M. Neal

Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan Health System, Ann Arbor, MI, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2010 in Vaccine
Verified
Journal Article
Closed access
JOJoanne M. O’hara
Joanne M. O’hara
LNLori M. Neal
Lori M. Neal
EMElizabeth A. McCarthy
Elizabeth A. McCarthy
JKJane A. Kasten-Jolly
Jane A. Kasten-Jolly
RBRobert N. Brey
Robert N. Brey
NMNicholas Mantis
Nicholas Mantis

1 January 2010 in Infection and Immunity
Verified
Journal Article
Closed access
LNLori M. Neal
Lori M. Neal
JOJoanne O'HAra
Joanne O'HAra
RBRobert N. Brey
Robert N. Brey
NMNicholas Mantis
Nicholas Mantis
Due to the potential use of ricin and other fast-acting toxins as agents of bioterrorism, there is an urgent need for the development of safe and effective antitoxin vaccines. A candidate ricin subunit vaccine (RiVax) consisting of a recombinant attenuated enzymatic A chain (RTA) has been shown to elicit protective antitoxin antibodies in mice and rabbits and is currently being tested in phase I human clinical trials. However, evaluation of the efficacy of this vaccine for humans is difficult for a number of reasons, including the fact that the key neutralizing B-cell epitopes on RTA have not been fully defined. Castelletti and colleagues (Clin. Exp. Immunol.136:365-372, 2004) recently identified a linear epitope on RTA, spanning residues L161 to I175, as a primary target of serum antibodies derived from humans who had been treated with ricin immunotoxin. While affinity-purified polyclonal IgG antibodies against this region of RTA were capable of neutralizing ricinin vitro, their capacity to confer protection against ricin challengein vivowas not determined. In this report, we describe the production and characterization of GD12, a murine monoclonal IgG1 antibody specifically directed against residues 163 to 174 (TLARSFIICIQM) of RTA. GD12 bound ricin holotoxin with high affinity (KD[dissociation constant], 2.9 × 10−9M) and neutralized it with a 50% inhibitory concentration of ∼0.25 μg/ml, as determined by a Vero cell-based cytotoxicity assay. Passive administration of GD12 was sufficient to protect BALB/c mice against intraperitoneal and intragastric ricin challenges. These data are important in terms of vaccine development, since they firmly establish that preexisting serum antibodies directed against residues 161 to 175 on RTA are sufficient to confer both systemic and mucosal immunity to ricin. The potential of GD12 to serve as a therapeutic following ricin challenge was not explored in this study.

1 September 2010 in Toxicon
Verified
Journal Article
Closed access
PWPaul G. Wahome
Paul G. Wahome
YBYan Bai
Yan Bai
LNLori M. Neal
Lori M. Neal
JRJon D. Robertus
Jon D. Robertus
NMNicholas Mantis
Nicholas Mantis

15 February 2016 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
GCGwo-Hsiao Chen
Gwo-Hsiao Chen
STSeagal Teitz-Tennenbaum
Seagal Teitz-Tennenbaum
LNLori M. Neal
Lori M. Neal
BMBenjamin J. Murdock
Benjamin J. Murdock
AMAntoni N. Malachowski
Antoni N. Malachowski
JOJohn J. Osterholzer
John J. Osterholzer
Patients with acquired deficiency in GM-CSF are susceptible to infections with Cryptococcus neoformans and other opportunistic fungi. We previously showed that GM-CSF protects against progressive fungal disease using a murine model of cryptococcal lung infection. To better understand the cellular and molecular mechanisms through which GM-CSF enhances antifungal host defenses, we investigated temporal and spatial relationships between myeloid and lymphoid immune responses in wild-type C57BL/6 mice capable of producing GM-CSF and GM-CSF–deficient mice infected with a moderately virulent encapsulated strain of C. neoformans (strain 52D). Our data demonstrate that GM-CSF deficiency led to a reduction in: 1) total lung leukocyte recruitment; 2) Th2 and Th17 responses; 3) total numbers of CD11b+ dendritic cells (DC) and CD11b− and CD11b+ macrophages (Mϕ); 4) DC and Mϕ activation; and 5) localization of DC and Mϕ to the microanatomic sites of alveolar infection. In contrast, GM-CSF deficiency resulted in increased accumulation of DC and Mϕ precursors, namely Ly-6Chigh monocytes, in the blood and lungs of infected mice. Collectively, these results show that GM-CSF promotes the local differentiation, accumulation, activation, and alveolar localization of lung DC and Mϕ in mice with cryptococcal lung infection. These findings identify GM-CSF as central to the protective immune response that prevents progressive fungal disease and thus shed new light on the increased susceptibility to these infections observed in patients with acquired GM-CSF deficiency.

12 June 2014 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
LNLori M Neal
Lori M Neal
LKLaura Jean Knoll
Laura Jean Knoll
Ly6C+ inflammatory monocytes are essential to host defense against Toxoplasma gondii, Listeria monocytogenes and other infections. During T. gondii infection impaired inflammatory monocyte emigration results in severe inflammation and failure to control parasite replication. However, the T. gondii factors that elicit these monocytes are unknown. Early studies from the Remington laboratory showed that mice with a chronic T. gondii infection survive lethal co-infections with unrelated pathogens, including L. monocytogenes, but a mechanistic analysis was not performed. Here we report that this enhanced survival against L. monocytogenes is due to early reduction of bacterial burdens and elicitation of Ly6C+ inflammatory monocytes. We demonstrate that a single TLR11/TLR12 ligand profilin (TgPRF) was sufficient to reduce bacterial burdens similar to T. gondii chronic infection. Stimulation with TgPRF was also sufficient to enhance animal survival when administered either pre- or post-Listeria infection. The ability of TgPRF to reduce L. monocytogenes burdens was dependent on TLR11 and required IFN-γ but was not dependent on IL-12 signaling. TgPRF induced rapid production of MCP-1 and resulted in trafficking of Ly6Chi CCR2+ inflammatory monocytes and Ly6G+ neutrophils into the blood and spleen. Stimulation with TgPRF reduced L. monocytogenes burdens in mice depleted with the Ly6G specific MAb 1A8, but not in Ly6C/Ly6G specific RB6-8C5 depleted or CCR2−/− mice, indicating that only inflammatory monocytes are required for TgPRF-induced reduction in bacterial burdens. These results demonstrate that stimulation of TLR11 by TgPRF is a mechanism to promote the emigration of Ly6Chi CCR2+ monocytes, and that TgPRF recruited inflammatory monocytes can provide an immunological benefit against an unrelated pathogen. Toxoplasma gondii is an apicomplexan parasite that can infect all warm blooded animals, but rodent species are considered the primary reservoirs. Mice that are infected with T. gondii become more resistant to lethal infection with other pathogens. Ly6C+ inflammatory monocytes are innate immune cells that are critical for defense against T. gondii and other infections. Mice with defects in the ability to recruit inflammatory monocytes fail to control T. gondii replication and succumb to overwhelming inflammation. In this study we used a co-infection model to explain why T. gondii-infected mice are more resistant to the bacterium Listeria monocytogenes. We show that stimulation of the rodent specific Toll-like receptor TLR11 by the T. gondii ligand profilin can recruit inflammatory monocytes, and that these monocytes can protect the host against L. monocytogenes. These findings make profilin an important tool for the study of monocyte biology during T. gondii infection of rodents and are especially interesting given that TLR11 is nonfunctional in humans and other vertebrates.

17 June 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
JXJintao Xu
Jintao Xu
LNLori M. Neal
Lori M. Neal
AGAnutosh Ganguly
Anutosh Ganguly
JKJessica L. Kolbe
Jessica L. Kolbe
JHJessica C. Hargarten
Jessica C. Hargarten
Michal A OlszewskiMichal A Olszewski
Michal A Olszewski
Cryptococcal meningoencephalitis (CM) is the major cause of infection-related neurological death, typically seen in immunocompromised patients. However, T cell–driven inflammatory response has been increasingly implicated in lethal central nervous system (CNS) immunopathology in human patients and murine models. Here, we report marked up-regulation of the chemokine receptor CXCR3 axis in human patients and mice with CM. CXCR3 deletion in mice improves survival, diminishes neurological deficits, and limits neuronal damage without suppressing fungal clearance. CD4+ T cell accumulation and TH1 skewing are reduced in the CNS but not spleens of infected CXCR3−/− mice. Adoptive transfer of WT, but not CXCR3−/− CD4+ T cells, into CXCR3−/− mice phenocopies the pathology of infected WT mice. Collectively, we found that CXCR3+CD4+ T cells drive lethal CNS pathology but are not required for fungal clearance during CM. The CXCR3 pathway shows potential as a therapeutic target or for biomarker discovery to limit CNS inflammatory damages.